Cellectis (NASDAQ:CLLS) Issues Earnings Results

Cellectis (NASDAQ:CLLS) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.22), Zacks reports. The firm had revenue of $33.22 million during the quarter, compared to analyst estimates of $5.90 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%.

Cellectis Price Performance

Shares of CLLS stock opened at $1.24 on Friday. Cellectis has a 1 year low of $1.14 and a 1 year high of $3.38. The firm’s 50 day moving average is $1.53 and its 200-day moving average is $1.83. The firm has a market capitalization of $68.92 million, a price-to-earnings ratio of -0.95 and a beta of 3.27. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of Cellectis in a research report on Thursday, February 27th. They issued a “buy” rating on the stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.